Mirador Therapeutics Expands Precision Immunology Pipeline Through Global Licensing Agreement for KP-301
Mirador Therapeutics, Inc., a clinical-stage biotechnology company focused on developing precision medicines for immune-mediated inflammatory and fibrotic diseases, has announced a significant expansion of its research and development pipeline through an exclusive worldwide licensing agreement with Kira Pharmaceuticals. The agreement grants Mirador global rights to develop, manufacture, and commercialize KP-301, a next-generation, potentially long-acting anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation.
The acquisition of KP-301 represents an important milestone for Mirador as it broadens its precision immunology portfolio into inflammatory vascular disease, an area where scientific understanding has advanced considerably but where many patients continue to face limited treatment options. The licensing agreement also includes access to related intellectual property, enabling Mirador to accelerate clinical development of the therapy while leveraging its proprietary precision medicine platform to identify the patients most likely to benefit.
Expanding Into Complement-Mediated Inflammatory Diseases
Inflammatory and autoimmune diseases remain among the most challenging therapeutic areas due to their biological complexity and the diverse mechanisms that drive disease progression. Among these pathways, the complement system has emerged as a critical regulator of inflammation and immune responses.
KP-301 specifically targets the C5a/C5aR signaling pathway, one of the most well-established inflammatory mechanisms involved in complement-mediated diseases. Excessive activation of this pathway contributes to persistent inflammation, tissue damage, and vascular injury across several autoimmune disorders.
By licensing KP-301, Mirador is entering a therapeutic space supported by strong biological validation while addressing persistent unmet clinical needs. The company believes the therapy has the potential to offer improved treatment durability and convenience compared with current approaches.
Addressing the Needs of Patients with ANCA-Associated Vasculitis
One of the primary development targets for KP-301 is ANCA-associated vasculitis (AAV), a rare but serious autoimmune disease characterized by inflammation and destruction of small blood vessels.
Patients with AAV often experience damage to multiple organs, including the kidneys, lungs, nervous system, and skin. Without effective treatment, the disease can lead to severe complications and permanent organ damage.
Over the past several years, inhibition of the C5a receptor has become an established therapeutic strategy for AAV. Clinical studies have demonstrated that suppressing C5a signaling can reduce inflammation, improve disease control, and decrease reliance on long-term corticosteroid therapy.
Although currently available therapies have demonstrated meaningful clinical benefit and commercial success, physicians continue to seek next-generation treatments that provide:
- Longer-lasting disease control
- Improved safety profiles
- Better patient tolerability
- Reduced dosing frequency
- Greater treatment convenience
- Enhanced long-term outcomes
Mirador believes KP-301 has been specifically engineered to address many of these remaining challenges.
A Differentiated Antibody Designed for Long-Acting Therapy
Unlike conventional complement inhibitors, KP-301 has been designed as a long-acting sweeping anti-C5a antibody capable of maintaining prolonged suppression of inflammatory signaling.
The antibody incorporates several advanced engineering technologies intended to improve both its effectiveness and durability.
Among its distinguishing features are:
- Potent and selective inhibition of C5a
- Long-acting pharmacological activity
- pH-dependent target binding
- Antibody recycling technology
- Durable target engagement
- Low-frequency dosing potential
One of the key scientific innovations behind KP-301 is its “sweeping” mechanism.
Traditional antibodies can become saturated when large amounts of inflammatory proteins are present, limiting their effectiveness and requiring more frequent dosing. KP-301 has been engineered to overcome this challenge through pH-dependent binding that allows the antibody to release its target within cellular compartments before being recycled back into circulation.
This recycling process enables a single antibody molecule to neutralize multiple C5a molecules over time, potentially extending therapeutic activity while reducing the amount of drug required.
As a result, the therapy is expected to provide sustained inhibition of C5a signaling with infrequent administration, making it particularly attractive for patients requiring chronic treatment.
Mirador’s Precision Medicine Strategy
The licensing agreement reflects Mirador’s broader corporate strategy of developing precision therapies that combine validated disease biology with therapeutic modalities optimized for specific patient populations.
Chairman and Chief Executive Officer Mark C. McKenna emphasized that the company’s approach focuses on selecting major unmet medical needs and matching each disease with the therapeutic technology most likely to deliver meaningful patient benefit.
According to McKenna, KP-301 represents an ideal example of this strategy. He noted that the biology underlying complement-driven vascular inflammation has been extensively validated, yet substantial unmet need remains for therapies capable of providing durable efficacy with favorable safety and tolerability.
He explained that the addition of KP-301 expands Mirador’s portfolio into inflammatory vascular disease while aligning with the company’s precision medicine philosophy of combining strong biological rationale, differentiated therapeutic design, and carefully selected disease targets.
Leveraging the Mirador360 Precision Development Engine
An important component of Mirador’s development strategy is its proprietary Mirador360™ (M360) precision development platform.
Rather than relying solely on traditional clinical development approaches, the company integrates large-scale molecular data analysis into every stage of therapeutic development.
The M360 platform currently incorporates more than 2.5 million molecular profiles collected across numerous immune-mediated diseases.
These data are used to support several critical activities, including:
- Identification of disease-driving biological targets
- Validation of therapeutic mechanisms
- Patient stratification
- Biomarker discovery
- Indication prioritization
- Clinical trial optimization
Through this precision medicine approach, Mirador aims to improve clinical development efficiency while increasing the likelihood of successful outcomes by identifying patients who are most likely to respond to treatment.
The company believes integrating KP-301 into this platform will facilitate both early clinical development and future expansion into additional inflammatory diseases.
Planned Clinical Development Timeline
Mirador has already outlined an ambitious development plan for KP-301 following completion of the licensing agreement.
The company expects to initiate a Phase 1 clinical trial by the end of 2026. This first-in-human study will primarily evaluate the antibody’s safety, tolerability, pharmacokinetics, and pharmacodynamic activity.
Assuming successful Phase 1 results, Mirador plans to launch a Phase 2 clinical study in patients with ANCA-associated vasculitis during the first half of 2027.
Beyond AAV, the company intends to investigate KP-301 across additional complement-mediated inflammatory diseases where excessive C5a signaling contributes to disease progression.
Future development strategies may include both:
- Monotherapy applications
- Combination treatment approaches alongside other immunomodulatory therapies
This broader clinical expansion could significantly increase the therapeutic potential of KP-301 across multiple autoimmune and inflammatory disorders.
Strengthening Mirador’s Immunology Portfolio
The addition of KP-301 further strengthens Mirador’s growing portfolio of precision immunology assets focused on treating chronic inflammatory diseases.
Rather than developing therapies across numerous unrelated disease areas, the company continues to build a pipeline centered on carefully selected biological pathways that have demonstrated strong clinical validation.
Complement-mediated inflammation represents one such pathway, supported by years of research establishing its role in autoimmune vascular diseases.
By combining advanced antibody engineering with precision patient selection, Mirador hopes to differentiate KP-301 from existing therapies while addressing important unmet clinical needs.
Financial Terms of the Agreement
Under the terms of the licensing agreement, Mirador receives exclusive worldwide rights to develop, manufacture, and commercialize KP-301 across all therapeutic indications.
Kira Pharmaceuticals will receive an upfront payment of $12 million upon execution of the agreement. In addition, Kira is eligible to receive future development, regulatory, and commercial milestone payments tied to the progress and success of the program.
The financial structure aligns the interests of both companies while providing Mirador with full operational control over global clinical development and commercialization activities.
The licensing of KP-301 marks an important strategic step for Mirador Therapeutics as it continues to expand its precision medicine pipeline into areas of significant unmet medical need. By targeting the validated C5a/C5aR inflammatory pathway with a long-acting, next-generation antibody, the company aims to develop a therapy that combines durable efficacy, convenient dosing, and improved patient outcomes.
Supported by its Mirador360 precision development engine and a growing portfolio of immune-focused therapies, Mirador is positioning itself to advance innovative treatments for autoimmune and inflammatory diseases. If clinical development proceeds as planned, KP-301 could emerge as a promising new option for patients with ANCA-associated vasculitis and other complement-mediated disorders, while reinforcing the company’s commitment to precision-driven innovation in immunology.
About Mirador Therapeutics
Mirador is a clinical-stage precision medicine company focused on developing first- and/or best-in-class next-generation therapeutics for immunology and inflammation. The company’s Mirador360™ precision development engine leverages the latest advances in human genetics and data science to rapidly deliver new precision medicines for patients living with immune-mediated inflammatory and fibrotic diseases. Mirador has raised over $650 million from leading life sciences investors and is based in San Diego, CA.